Necessity and sufficiency

Flex is not dead: Why WeWork's collapse won't spell the end of the industry

Retrieved on: 
星期四, 二月 22, 2024
TEC, Necessity and sufficiency, WeWork, Multinational corporation, Culture, IPO, Bankruptcy, City, CBD

This expansion was driven more by the desire for quick scaling rather than actual market demand.

Key Points: 
  • This expansion was driven more by the desire for quick scaling rather than actual market demand.
  • Its leadership faced criticism for opaque decision-making and misallocation of funds, leading to a loss of investor trust and market confidence.
  • The company's failed IPO in 2019 marked a turning point, shedding light on its overvaluation and questionable governance practices.
  • The flexible workspace industry shows significant long-term potential, and operators with strong foothold in the sector, such as The Executive Centre, will only grow stronger.

Dragos OT Cybersecurity “Year in Review” Reports Rise in Geopolitically Driven Attacks, Ransomware, and Threat Groups

Retrieved on: 
星期二, 二月 20, 2024
Software, Technology, Data Management, Security, Internet, Necessity and sufficiency, Research, Commonwealth, POC, Aviation, Stage 2, Government, Rockwell Automation, Independence, Hacktivism, OT, Organization, ICS, Telecommunications, Denial-of-service attack, Environment, Inc., Separate, Oracle Applications, Arms industry

Dragos Inc., the global leader in cybersecurity for operational technology (OT) environments, today released its sixth annual Dragos OT Cybersecurity Year in Review report, the most comprehensive report on cyber threats facing industrial organizations.

Key Points: 
  • Dragos Inc., the global leader in cybersecurity for operational technology (OT) environments, today released its sixth annual Dragos OT Cybersecurity Year in Review report, the most comprehensive report on cyber threats facing industrial organizations.
  • “OT cyber threats reached a tipping point in 2023,” said Robert M. Lee, co-founder and CEO of Dragos.
  • With these additions, Dragos analysts now track 21 Threat Groups worldwide that have been observed as being engaged in OT operations in 2023.
  • The 2023 Dragos OT Cybersecurity Year in Review is an annual overview and analysis of OT-focused global threat activities, vulnerabilities, and industry insights and trends.

Matinas BioPharma Provides Business Update and 2023 Strategic Outlook

Retrieved on: 
星期一, 一月 30, 2023
Transfer, Biomedical Advanced Research and Development Authority, RNA, Necessity and sufficiency, Disease, Lipofectamine, Food, Phase II, Safety, Oligonucleotide, Mycosis, Attention, HeLa, Mucormycosis, NYSE, BioNTech, Gene expression, Evaluation, Mucor, Sirna, Vaccine, ASO, Cryptococcosis, Aspergillosis, Survival, Therapy, Conference, Gilead, BARDA, Internal, COVID, HEK293, Patient, Enactment, Clinical trial, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FDA, Aspergillus, LNC, Organic acid, Hand, Candidiasis, Genentech, Coccidioidomycosis, Medicine, Asos, Development, RNA transfection, Sirna Therapeutics, Toxicity, Fine chemical, Pharmaceutical industry, Matina Brothers

ET

Key Points: 
  • ET
    BEDMINSTER, N.J., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB, Matinas), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology, today is providing a business update on its ongoing programs and discussing its strategic outlook for 2023.
  • Our ongoing collaborations with BioNTech and, recently, National Resilience, have aligned Matinas with two of the world’s leading companies in the gene therapy space.
  • The Company will host a live conference call and webcast to discuss this corporate update and 2023 business outlook today, Monday, January 30 at 4:30 p.m.
  • The live webcast will be accessible on the Investors section of Matinas BioPharma’s website, www.matinasbiopharma.com , and archived for 90 days.

Breaking: FDA permits pharmacists to prescribe Paxlovid to treat COVID-19

Retrieved on: 
星期三, 七月 6, 2022
Federation, FDA, View, Patient, CEO, Pharmacist, CMS, COVID-19, Health equity, Therapy, Doctor of Pharmacy, COVID-19 vaccine, Pharmacy technician, Necessity and sufficiency, JD, American Pharmacists Association, Pharmacy, EUA, Multimedia, American, CDC, Pharmaceutical industry, Healthcare

WASHINGTON, July 6, 2022 /PRNewswire/ -- Today, after months of effort by the American Pharmacists Association (APhA) and other stakeholders, FDA has updated the EUA for the COVID-19 oral antiviral, Paxlovid, to permit pharmacists to order and prescribe Paxlovid under certain conditions.

Key Points: 
  • WASHINGTON, July 6, 2022 /PRNewswire/ -- Today, after months of effort by the American Pharmacists Association (APhA) and other stakeholders, FDA has updated the EUA for the COVID-19 oral antiviral, Paxlovid, to permit pharmacists to order and prescribe Paxlovid under certain conditions.
  • The FDA will permit pharmacists to order and prescribe Paxlovid, the COVID-19 oral antiviral, under certain conditions.
  • The federal government had already authorized pharmacists to order and dispense oral therapeutics under the PREP Act.
  • However, the ability for all pharmacists to prescribe was not included under the conditions in the original EUA for Paxlovid.

Matinas BioPharma Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights

Retrieved on: 
星期二, 三月 8, 2022
Form 10-K, Cryptococcosis, Allergy, Enrollment, LNC, Cohort, Infection, Nucleic acid, Degenerative disease, University of North Carolina at Greensboro, Science, Chapel Hill, Cystic fibrosis, Partnership, Auris, Private Securities Litigation Reform Act, Vaccine, Necessity and sufficiency, Forward-looking statement, Organic acid, European Medicines Agency, FDA, Solution, SEC, Company, Consultant, National Institute, Clinical trial, NTM, Enactment, EPA, Candida auris, Department, Investor, Food, NIAID, EMA, Hand, NYSE, Cystic Fibrosis Foundation, Sale, Mucormycosis, Risk, Technology, Asos, RNA transfection, Mycosis, NDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Research, DNA, Safety, University, UNC, Conference, SAD, DPA, DSMB, GLOBE, Therapy, Pharmaceutical industry

Preclinical studies of MAT2203 in Candida auris and mucormycosis (black fungus) scheduled to begin in the second quarter of 2022 to support potential label expansion.

Key Points: 
  • Preclinical studies of MAT2203 in Candida auris and mucormycosis (black fungus) scheduled to begin in the second quarter of 2022 to support potential label expansion.
  • Cash, cash equivalents and marketable securities at December 31, 2021, were approximately $49.6 million, compared to $58.7 million at December 31, 2020.
  • With the support of the Cystic Fibrosis Foundation, MAT2501 is currently undergoing important preclinical studies and commenced a Phase 1 human clinical trial in the fourth quarter of 2021.
  • Matinas BioPharmas product candidates are all in a development stage and are not available for sale or use.

Quanergy Secures Orders for Over 1,000 Sensors for IoT Applications

Retrieved on: 
星期四, 二月 17, 2022
Technology, Construction & Property, Semiconductor, Urban Planning, Transport, Other Technology, Software, Building Systems, Hardware, Logistics, Supply Chain Management, Behavior, NYSE, Intellectual property, CMOS, Government, Forward-looking statement, Necessity and sufficiency, Solution, Transport, Innovation, System, City, Safety, OPA, Technology, Lidar, U.S. Securities and Exchange Commission, Â, New, 3D, Automation, Private Securities Litigation Reform Act, Growth, Multimedia, COVID-19, Electricity, General manager, 3D printing, Surveying, Risk management, IOT, Quanergy

Quanergy Systems, Inc. , (NYSE: QNGY and QNGY.WS) a leading provider of OPA-based solid-state LiDAR sensors and smart 3D solutions for automotive and IoT, announced today that in Q4, 2021 the company secured orders for over 1,000 sensors for a broad range of IoT applications.

Key Points: 
  • Quanergy Systems, Inc. , (NYSE: QNGY and QNGY.WS) a leading provider of OPA-based solid-state LiDAR sensors and smart 3D solutions for automotive and IoT, announced today that in Q4, 2021 the company secured orders for over 1,000 sensors for a broad range of IoT applications.
  • Quanergy is expanding our business and helping us deliver new solutions, said Bin Liu, President at Shanghai Wise.
  • We are using Quanergy to provide inventive solutions to businesses across transportation, energy, manufacturing and logistics.
  • The orders secured for over 1,000 sensors underscore the business impact that our smart LiDAR solutions are providing customers and partners worldwide to unlock the full power of their IoT applications.

IFF Appoints Nicolas Mirzayantz President of IFF’s Nourish Division

Retrieved on: 
星期三, 七月 28, 2021
Cosmetics, Retail, Chemicals, Plastics, Manufacturing, Specialty, Food, Beverage, If and only if, Necessity and sufficiency

IFF (NYSE: IFF) today announced that Nicolas Mirzayantz, current President, Scent, has been appointed President of IFFs Nourish division, effective September 1, 2021.

Key Points: 
  • IFF (NYSE: IFF) today announced that Nicolas Mirzayantz, current President, Scent, has been appointed President of IFFs Nourish division, effective September 1, 2021.
  • Mr. Mirzayantz will succeed Kathy Fortmann, current President, Nourish, who has decided to pursue other opportunities outside of IFF.
  • We could not be more pleased to have Nicolas lead our Nourish division, said IFF Chairman and CEO, Andreas Fibig.
  • Nicolas is joining a Nourish division with a tremendous opportunity to build on significant sales momentum and strong customer interest in IFFs differentiated portfolio and capabilities.

Kaiser Aluminum Corporation Announces Private Placement of New Senior Notes and Conditional Redemption of Outstanding Senior Notes

Retrieved on: 
星期二, 五月 11, 2021
Articles, Philosophy, Branches of philosophy, Communication, Forward-looking statement, Henry J. Kaiser, Kaiser Aluminum, Necessity and sufficiency, Fact

The consummation of the offering of notes is subject to market conditions.\nOn May 11, 2021, Kaiser Aluminum provided conditional notice of its intent to redeem the 2025 notes on May 21, 2021.

Key Points: 
  • The consummation of the offering of notes is subject to market conditions.\nOn May 11, 2021, Kaiser Aluminum provided conditional notice of its intent to redeem the 2025 notes on May 21, 2021.
  • These statements are based on the beliefs and assumptions of management based on information available to it at the time such statements are made.
  • Kaiser Aluminum cautions that any forward-looking statements are not guarantees of future performance and involve significant risks and uncertainties, and that actual results may vary materially from those in the forward-looking statements as a result of various factors.
  • Kaiser Aluminum undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in Kaiser Aluminum\xe2\x80\x99s expectations.\nInvestor Relations and Public Relations Contact:\n"

IFF to Complete Merger With DuPont’s Nutrition & Biosciences Business

Retrieved on: 
星期一, 二月 1, 2021
Cosmetics, Retail, Food, Beverage, Fashion, If and only if, Necessity and sufficiency, FO, International Flavors & Fragrances

IFF (NYSE: IFF) to complete the previously announced merger of IFF and DuPonts Nutrition & Biosciences (N&B) business, pursuant to a Reverse Morris Trust transaction today.

Key Points: 
  • IFF (NYSE: IFF) to complete the previously announced merger of IFF and DuPonts Nutrition & Biosciences (N&B) business, pursuant to a Reverse Morris Trust transaction today.
  • Shares of the combined companys common stock will trade on the New York Stock Exchange under the symbol IFF.
  • Through an unprecedented last 12 months, both the IFF and N&B teams have remained incredibly focused on executing our respective business plans and setting the foundation to bring this combination to life.
  • Im extremely proud of what our teams have accomplished to complete the transaction on time despite a year of unprecedented challenges.

IFF Previews Financial Profile, Governance and Strategic Transformation Initiatives Effective at Completion of Combination with DuPont N&B

Retrieved on: 
星期一, 一月 11, 2021
Cosmetics, Retail, Chemicals, Plastics, Manufacturing, Specialty, Food, Beverage, If and only if, Necessity and sufficiency

IFF will be a new Company for a new era, said IFF Chairman and CEO, Andreas Fibig.

Key Points: 
  • IFF will be a new Company for a new era, said IFF Chairman and CEO, Andreas Fibig.
  • Customers across end markets expect more from their value chain partners and the new IFF is well-positioned to deliver.
  • I would also like to thank and acknowledge the four directors that will be departing our Board upon the completion of the merger.
  • Marcello, David, Katherine and Li-Huei have provided invaluable leadership and expertise as IFF has pursued our transformation and created this foundation for our next stage of growth.